BACKGROUND: Despite cannabis being the most widely used illicit substance in the United States, individuals diagnosed with cannabis use disorder (CUD) have few well-researched, affordable treatment options available to them. Although found to be effective for improving treatment outcomes in other drug populations, exercise is an affordable and highly accessible treatment approach that has not been routinely investigated in cannabis users. OBJECTIVES: The aim of this paper is to inform the topic regarding exercise's potential as an adjunctive treatment for individuals with CUD. METHODS: We reviewed the evidence surrounding cannabis use and its current treatment in the United States, explored the rationale for including exercise in the treatment of substance use disorders (SUDs), and in particular, proposed a biological mechanism (i.e., endocannabinoids (eCBs)) that should be examined when utilizing exercise for the treatment of CUD. RESULTS: Cannabis use is widespread and increasing in the United States. Chronic, heavy cannabis use may dysregulate the endogenous cannabinoid system, which has implications for several psychobiological processes that interact with the eCB system such as reward processing and the stress response. Given that exercise is a potent activator of the eCB system, it is mechanistically plausible that exercise could be an optimal method to supplement cessation efforts by reducing psychophysical withdrawal, managing stress, and attenuating drug cravings. CONCLUSION: We suggest there is a strong behavioral and physiological rationale to design studies which specifically assess the efficacy of exercise, in combination with other therapies, in treating CUD. Moreover, it will be especially important to include the investigation of psychobiological mechanisms (e.g., eCBs, hippocampal volume), which have been associated with both exercise and SUDs, to examine the broader impact of exercise on behavioral and physiological responses to treatment.
BACKGROUND: Despite cannabis being the most widely used illicit substance in the United States, individuals diagnosed with cannabis use disorder (CUD) have few well-researched, affordable treatment options available to them. Although found to be effective for improving treatment outcomes in other drug populations, exercise is an affordable and highly accessible treatment approach that has not been routinely investigated in cannabis users. OBJECTIVES: The aim of this paper is to inform the topic regarding exercise's potential as an adjunctive treatment for individuals with CUD. METHODS: We reviewed the evidence surrounding cannabis use and its current treatment in the United States, explored the rationale for including exercise in the treatment of substance use disorders (SUDs), and in particular, proposed a biological mechanism (i.e., endocannabinoids (eCBs)) that should be examined when utilizing exercise for the treatment of CUD. RESULTS: Cannabis use is widespread and increasing in the United States. Chronic, heavy cannabis use may dysregulate the endogenous cannabinoid system, which has implications for several psychobiological processes that interact with the eCB system such as reward processing and the stress response. Given that exercise is a potent activator of the eCB system, it is mechanistically plausible that exercise could be an optimal method to supplement cessation efforts by reducing psychophysical withdrawal, managing stress, and attenuating drug cravings. CONCLUSION: We suggest there is a strong behavioral and physiological rationale to design studies which specifically assess the efficacy of exercise, in combination with other therapies, in treating CUD. Moreover, it will be especially important to include the investigation of psychobiological mechanisms (e.g., eCBs, hippocampal volume), which have been associated with both exercise and SUDs, to examine the broader impact of exercise on behavioral and physiological responses to treatment.
Entities:
Keywords:
Exercise; anandamide; cannabis use disorder; endocannabinoid; treatment
Authors: Hanna Karen Moreira Antunes; Geovana Silva Fogaça Leite; Kil Sun Lee; Amaury Tavares Barreto; Ronaldo Vagner Thomatieli Dos Santos; Helton de Sá Souza; Sergio Tufik; Marco Tulio de Mello Journal: Physiol Behav Date: 2016-01-23
Authors: Daniela Muhl; Markus Kathmann; Carolin Hoyer; Laura Kranaster; Martin Hellmich; Christoph W Gerth; Johannes Faulhaber; Eberhard Schlicker; F Markus Leweke Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2014-05-02 Impact factor: 3.000
Authors: Johannes Fuss; Jörg Steinle; Laura Bindila; Matthias K Auer; Hartmut Kirchherr; Beat Lutz; Peter Gass Journal: Proc Natl Acad Sci U S A Date: 2015-10-05 Impact factor: 11.205
Authors: M Feuerecker; D Hauer; R Toth; F Demetz; J Hölzl; M Thiel; I Kaufmann; G Schelling; A Choukèr Journal: Eur J Appl Physiol Date: 2011-11-19 Impact factor: 3.078
Authors: E Heyman; F-X Gamelin; M Goekint; F Piscitelli; B Roelands; E Leclair; V Di Marzo; R Meeusen Journal: Psychoneuroendocrinology Date: 2011-10-24 Impact factor: 4.905
Authors: Denise C Vidot; Chad D Rethorst; Tom J Carmody; Mark Stoutenberg; Robrina Walker; Tracy L Greer; Madhukar H Trivedi Journal: Drug Alcohol Depend Date: 2019-05-07 Impact factor: 4.492
Authors: Kaleen M Lavin; Paul M Coen; Liliana C Baptista; Margaret B Bell; Devin Drummer; Sara A Harper; Manoel E Lixandrão; Jeremy S McAdam; Samia M O'Bryan; Sofhia Ramos; Lisa M Roberts; Rick B Vega; Bret H Goodpaster; Marcas M Bamman; Thomas W Buford Journal: Compr Physiol Date: 2022-03-09 Impact factor: 8.915
Authors: James P Coxon; Robin F H Cash; Joshua J Hendrikse; Nigel C Rogasch; Ellen Stavrinos; Chao Suo; Murat Yücel Journal: J Physiol Date: 2017-12-27 Impact factor: 5.182
Authors: Hugues Sampasa-Kanyinga; Ian Colman; Gary S Goldfield; Ian Janssen; JianLi Wang; Hayley A Hamilton; Jean-Philippe Chaput Journal: Int J Environ Res Public Health Date: 2021-03-23 Impact factor: 3.390